Sign In
Buy CGEM
$15.21
-0.130 (-0.85%)
At Close: Jun 03, 2026
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
07:00am, Thursday, 20'th Nov 2025
PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune d
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
07:00am, Thursday, 06'th Nov 2025
Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to b
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate obse
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a cl
Cullinan Therapeutics: Worthy Of A Small Position
07:01am, Friday, 17'th Oct 2025
Cullinan Therapeutics is down some 70% since May 2024, mainly due to lack of data from its autoimmune candidate CLN-978. CLN-978, an off-the-shelf CD19xCD3 T-cell engager, targets autoimmune diseases
PRINCETON, N.J. and CAMBRIDGE, Mass.
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
11:26am, Tuesday, 23'rd Sep 2025
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
07:00am, Friday, 12'th Sep 2025
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies
Cullinan Therapeutics, Inc. (CGEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
10:50am, Wednesday, 10'th Sep 2025
Cullinan Therapeutics, Inc. (NASDAQ:CGEM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Chad Messer Nadim Ahmed - President, CEO & Direct
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
05:30am, Tuesday, 09'th Sep 2025
Updated efficacy and safety data to be presented from the REZILIENT1 trial of zipalertinib from the cohort of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor recepto
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 21'st Aug 2025
CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies,
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
07:00am, Thursday, 07'th Aug 2025
CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst
10:24pm, Tuesday, 15'th Jul 2025
CGEM has an interesting “modality‑agnostic” approach that focuses on targets first, then models yield the most promising candidates. This way, CGEM has built a relatively well-diversified oncolo
Advances Cullinan's leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline
